Core binding factor acute myeloid leukaemia and c-KIT mutations

Oncology Reports

Volumn 29, Issue 5, 2013, Pages 1859-1866

  Riera, Ludovica ^a,b   Marmont, Filippo ^c   Toppino, Daniela ^b   Frairia, Chiara ^c   Sismondi, Francesca ^a,b   Audisio, Ernesta ^c   Di Bello, Cristiana ^b   D'Ardia, Stefano ^c   Di Celle, Paola Francia ^b   Messa, Emanuela ^c   Inghirami, Giorgio ^a,b   Vitolo, Umberto ^c   Pich, Achille ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Dermatopathology Section Azienda Ospedaliera Città della Salute e della Scienza   (Italy)

Author keywords

Acute myeloid leukaemia; c KIT mutations; Core binding factor; Lactate dehydrogenase; Prognosis

Indexed keywords

CORE BINDING FACTOR; CYTARABINE; ETOPOSIDE; IDARUBICIN; LACTATE DEHYDROGENASE; ANTINEOPLASTIC AGENT; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CANCER INCIDENCE; CANCER PROGNOSIS; CELL PROLIFERATION; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; ENZYME BLOOD LEVEL; EXON; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; MALE; MUTATIONAL ANALYSIS; ONCOGENE C KIT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; BONE MARROW; CHROMOSOME ABERRATION; DRUG EFFECTS; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; MUTATION; PROCEDURES; PROGNOSIS; STEM CELL TRANSPLANTATION; YOUNG ADULT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHROMOSOME ABERRATIONS; CORE BINDING FACTORS; CYTARABINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; EXONS; FEMALE; HUMANS; IDARUBICIN; L-LACTATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; YOUNG ADULT;

EID: 84895579017     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2328     Document Type: Article

References (26)

1. Speck NA and Gilliland DG: Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2: 502-513, 2002. (Pubitemid 37328932)
2. Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman JW, Porwit A, Thiele J and Bloomfield CD: Acute myeloid leukaemia with recurrent genetic abnormalities. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, Thiele J and Vardiman JW (eds). 4th edition. IARC Press, Lyon, pp110-112, 2008.
3. Mrózek K, Heinonen K, Lawrence D, Carroll AJ, Koduru PR, Rao KW, Strout MP, Hutchison RE, Moore JO, Mayer RJ, Schiffer CA and Bloomfield CD: Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: a Cancer and Leukemia Group B Study. Blood 90: 4532-4538, 1997. (Pubitemid 27508459)
4. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC and Mayer RJ: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58: 4173-4179, 1998. (Pubitemid 28440576)
5. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A and Goldstone A: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92: 2322-2333, 1998. (Pubitemid 28452973)
6. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, Kolitz JE, Larson RA and Bloomfield CD; Cancer and Leukemia Group B: Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 24: 3904-3911, 2006. (Pubitemid 46630738)
7. Park SH, Chi HS, Min SK, Park BG, Jang S and Park CJ: Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res 35: 1376-1383, 2011.
8. Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR, Schiffer CA and Bloomfield CD: Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 90: 1643-1648, 1997. (Pubitemid 27355438)
9. Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F, Lamy T, Auvrignon A, Blaise D, Pigneux A, Mugneret F, Bastard C, Dastugue N, Van den Akker J, Fière D, Reiffers J, Castaigne S, Leverger G, Harousseau JL and Dombret H; French Acute Myeloid Leukemia Intergroup; Groupe Ouest-Est des Leucémies Aiguës Myéoblastiques; Leucémies Aiguës Myéoblastiques de l'Enfant; Acute Leukemia French Association; Bordeaux-Grenoble-Marseille-Toulouse cooperative groups: Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood 102: 462-469, 2003.
10. Schlenk RF, Benner A, Krauter J, Büchner T, Sauerland C, Ehninger G, Schaich M, Mohr B, Niederwieser D, Krahl R, Pasold R, Döhner K, Ganser A, Döhner H and Heil G: Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 22: 3741-3750, 2004. (Pubitemid 41102131)
11. Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA and Bloomfield CD: Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 23: 5705-5717, 2005.
12. Marková J, Marková J, Trnková Z, Michková P, Maaloufová J, Starý J, Cetkovský P and Schwarz J: Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. Leuk Lymphoma 50: 1448-1460, 2009.
13. Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R, Nassar A, Sobin LH and Miettinen M: Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 157: 1091-1095, 2000.
14. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD and Fletcher JA: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61: 8118-8121, 2001. (Pubitemid 33091601)
15. Miselli FC, Casieri P, Negri T, Orsenigo M, Lagonigro MS, Gronchi A, Fiore M, Casali PG, Bertulli R, Carbone A, Pierotti MA, Tamborini E and Pilotti S: c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. Clin Cancer Res 13: 2369-2377, 2007. (Pubitemid 46698586)
16. Kottaridis PD, Gale RE and Linch DC: Flt3 mutations and leukaemia. Br J Haematol 122: 523-538, 2003. (Pubitemid 36995209)
17. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M and Ehninger G: Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107: 4011-4020, 2006. (Pubitemid 43726809)
18. Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, Uitterlinden AG, Erpelinck CA, Delwel R, Löwenberg B and Valk PJ: Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106: 3747-3754, 2005. (Pubitemid 41739008)
19. Gulley ML, Shea TC and Fedoriw Y: Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia (Review). J Mol Diagn 12: 3-16, 2010.
20. Sangle NA and Perkins SL: Core-binding factor acute myeloid leukemia. Arch Pathol Lab Med 135: 1504-1509, 2011.
21. Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT, Dewald GW, Kantarjian HM, Pierce SR and Estey EH: The clinical spectrum of adult acute myeloid leukaemia associated with corebinding factor translocations. Br J Haematol 135: 165-173, 2006. (Pubitemid 44401613)
22. Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, Sauerland MC, Berdel W, Buchner T and Hiddemann W: Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 101: 64-70, 2003. (Pubitemid 36025888)
23. Germing U, Hildebrandt B, Pfeilstöcker M, Nösslinger T, Valent P, Fonatsch C, Lübbert M, Haase D, Steidl C, Krieger O, Stauder R, Giagounidis AA, Strupp C, Kündgen A, Mueller T, Haas R, Gattermann N and Aul C: Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 19: 2223-2231, 2005. (Pubitemid 41741618)
24. Spoo AC, Lübbert M, Wierda WG and Burger JA: CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 109: 786-791, 2007. (Pubitemid 46105982)
25. Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A, Raffoux E, Leblanc T, Thomas X, Hermine O, Quesnel B, Baruchel A, Leverger G, Dombret H and Preudhomme C; Acute Leukemia French Association (ALFA); Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Groups: Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 20: 965-970, 2006. (Pubitemid 43797286)
26. Dombret H, Preudhomme C and Boissel N: Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? Curr Opin Hematol 16: 92-97, 2009.